Back to search
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
Squamous Cell Carcinoma of Head and Neck
Clinicaltrials.gov:
EU CTIS:
#2023-508418-40-00
Other:
#61186372HNC2002
Interested in this trial?
Subscribe or share this trial
Trials at a glance
Status
Enrolling
Condition
Squamous Cell Carcinoma of Head and Neck
Trial type
Interventional
Trial phase
Phase 1
Investigational
product
product
Amivantamab
Carboplatin
Paclitaxel
Pembrolizumab
Age
18+ years old
Biological sex
All
Placebo?
No
Trial start date
April 22, 2024
Trial end date
December 27, 2032
CT.gov ID
#NCT06385080
Share the trial ID with your doctor to see if trial participation is right for you. Participation depends on an independent medical assessment.
Countries:
- China,
- France,
- Germany,
- Japan,
- Malaysia,
- Poland,
- South Korea,
- Spain,
- Taiwan,
- United Kingdom,
- United States
Loading...
Enrolling
Cambridge, United Kingdom, CB2 0QQ
Enrolling
Nagoya, Japan, 464-8681
Enrolling
Seoul, South Korea, 05505
Enrolling
Beijing, China, 100142
Enrolling
Nantes, France, 44000
Enrolling
Lille, France, 59000
Enrolling
Gliwice, Poland, 44-102
Enrolling
Changhua, Taiwan, 500
Enrolling
Cleveland, Ohio, United States, 44195
Enrolling
Shanghai, China, 200032
Enrolling
Villejuif, France, 94805
Enrolling
Barcelona, Spain, 08035
Enrolling
Madrid, Spain, 28041
Enrolling
Madrid, Spain, 28034
Enrolling
London, United Kingdom, W12 0HS
Enrolling
Barcelona, Spain, 08908
Enrolling
Paris, France, 75248
Enrolling
Avignon, France, 84918
Enrolling
Kaohsiung City, Taiwan, 833
Enrolling
Detroit, Michigan, United States, 48201 2013
Enrolling
Stuttgart, Germany, 70174
Enrolling
Taoyuan District, Taiwan, 33382
Enrolling
Linyi, China, 276002
Enrolling
Warsaw, Poland, 02 781
Enrolling
Taipei, Taiwan, 100
Enrolling
Kuala Lumpur, Malaysia, 59100
Enrolling
London, United Kingdom, SW3 6JJ
Enrolling
London, United Kingdom, SM2 5PT
Enrolling
New Brunswick, New Jersey, United States, 08901
Enrolling
Seoul, South Korea, 06351
Enrolling
Seoul, South Korea, 03080
Enrolling
Seoul, South Korea, 03722
Enrolling
Shanghai, China, 200120
Enrolling
Taipei, Taiwan, 112
Enrolling
Manchester, United Kingdom, M20 4BX
Enrolling
Guildford, United Kingdom, GU2 7XX
Enrolling
Chicago, Illinois, United States, 60637
Enrolling
Tokyo, Japan, 160-0023
Enrolling
Wuhan, China, 430022
Enrolling
Essen, Germany, 45147
Enrolling
London, United Kingdom, W1T 7HA
Enrolling
Kuala Lumpur, Malaysia, 59100
Enrolling
Aurora, Colorado, United States, 80045
Enrolling
Baltimore, Maryland, United States, 21201
Enrolling
Ann Arbor, Michigan, United States, 48109
Enrolling
Chapel Hill, North Carolina, United States, 27599
Enrolling
Salt Lake City, Utah, United States, 84112
Enrolling
Charlottesville, Virginia, United States, 22903
Enrolling
Gdansk, Poland, 80 214
Enrolling
Fairfax, Virginia, United States, 22031
Enrolling
St Louis, Missouri, United States, 63110
Enrolling
Cheng Du Shi, China, 610041
Enrolling
New Haven, Connecticut, United States, 06520
Completed
Leipzig, Germany, 04103
Completed
La Jolla, California, United States, 92093
#
More than 50 sites in this region
#
More than 10 sites in this region
#
Less than 10 sites in this region
Individual sites
Access detailed information on the trial:
Clinical trials information
© Johnson & Johnson and its affiliates 2026
